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Abstract This overview of the pub-
lished epidemiological evidence of
migraine helps to identify the size of
the public-health problem that
migraine represents. It also highlights
the need for further epidemiological
studies in many parts of the world to
gain full understanding of the scale
of clinical, economic and humanistic
burdens attributable to it. This paper
presents some of the work on
migraine undertaken by the World
Health Organization (WHO) in the
Global Burden of Disease study con-
ducted in 2000 and reported in the
World Health Report 2001. Migraine
was not included in the first Global
Burden of Disease 1990. The paper
also discusses the measurement of
disability attributable to headache
disorders using WHO ICF
Classification. Using disability-
adjusted life years (DALYs) as a
summary measure of population
health (which adds disability to mor-
tality), WHO has shown that mental
and neurological disorders collective-
ly account for 30.8% of all years of
healthy life lost to disability (YLDs)
whilst migraine, one amongst these,
alone accounts for 1.4% and is in the
top 20 causes of disability world-
wide. This information is combined
with the increasingly widely accepted
belief that disability and functioning
are relevant parameters for monitor-
ing the health of nations and that
there is an increasing need to mea-
sure them. WHO’s Classification of
Functioning, Disability and Health
(ICF) provides a model of human
functioning and disability, as well as
a classification system, that allows us
to highlight and measure all dimen-
sions of disability. ICF applied to
headache disorders allows compara-
bility with other health conditions as
well as evaluation of the role of the
environment as a cause of disability
amongst people with headache.
Migraine causes a large proportion of
the non-fatal disease-related burden
worldwide.Our knowledge of
headache related burden is incom-
plete and it is necessary to add to it
epidemiological studies in many parts
of the world and to combine this with
measurements of disability using
both DALYs and WHO’s ICF
Classification. The work described
here has been the base for the Global
Campaign against Headache disor-
ders: “Lifting the Burden”, launched
in 2004 jointly by WHO, IHS
(International Headache Society),
WHA (World Headache Alliance)
and EHF (European Headache
Federation).
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Introduction
The recognition that headache disorders are greatly bur-
densome worldwide and, consequently, a global public-
health problem is slowly changing attitudes towards them.
These common neurological complaints significantly
damage health and lifestyle: almost all people with
migraine and 60% of those with tension-type headache
experience reductions in social activities and work capac-
ity. Despite this, both the public and the majority of
health-care professionals still tend to perceive headache
disorders as minor or trivial complaints. As a result, the
physical, emotional, social and economic burdens
imposed by headache disorders are poorly acknowledged
and these disorders are seen as unimportant in the priority
order for health-care resource allocation.
Whilst financial costs of headache, due mainly to lost
productivity, are very high in the developed economies
where they have been measured [1], it is right to consider
the impact of headache disorders on public health more
from a humanitarian perspective of suffering rather than
limit the discussion to one focused on these costs alone [2].
The World Health Organization (WHO), at a consensus
conference on the public-health impact of headache disor-
ders, produced several recommendations; amongst them
was underlined the need to evaluate burden more general-
ly in assessing the importance of these disorders [3].
Epidemiology is the essential starting point in assess-
ing the burden of a disease. The epidemiology of
headache disorders is only partly documented; for exam-
ple, migraine is the most extensively studied headache
disorder, while the more common tension-type headache
and the more disabling cluster headache and subtypes of
chronic daily headache have been less well investigated.
In addition, because of the high cost of conducting large-
scale studies, because of obstacles in the way of access to
the general population and because headache is accorded
low priority in regions where communicable diseases may
pose a greater threat to public health, definitive epidemio-
logical data for most developing countries is lacking
across all headache types [4].
Change has taken place over the past 15 years – slow-
ly, but gathering pace. Important epidemiological papers
[5–8], joining extensive work on pathophysiology and a
revised headache classification (ICHD II) [9], have pro-
duced clear evidence of the public-health importance of
headache disorders and their impact on people and society.
The contemporaneous appearance at an international level
of the concept of “sustainable medicine” as a basis for allo-
cation of the available health-care resources, which in the
case of headache is ill-matched to the high levels of health-
care need, has led headache research groups to work close-
ly with health economists, public-health administrators
and lay organisations in developing ideas for best practice
to meet these needs. One result was the work on burden of
migraine undertaken by WHO and reported in the World
Health Report 2001 [10, 11]. This work has been the base
for the Global Campaign to reduce the burden of headache
worldwide known as “Lifting the Burden”, which was
launched in 2004 jointly by WHO, the International
Headache Society (IHS), the World Headache Alliance
(WHA) and the European Headache Federation (EHF).
The global burden of disease (GBD) studies
Decision-makers need the best available evidence in mat-
ters of interest to them. Obtaining it means systematically
identifying and assembling all the relevant evidence then
available, and assessing its quality, limitations and uncer-
tainty in order to use it to best effect in producing quanti-
ty estimates.
“Best available”, however, is not always good.
Nonetheless, concerns about poor quality or uncertainty
of data are not an acceptable reason for rejecting such evi-
dence, as decisions must often be made now: decision-
makers cannot and will not wait years for improvement in
evidence. In relation to international efforts to improve
the health of populations, this applies perfectly to quan-
tifications of the burden of disease – existing now and
likely to exist in the future – on which health-care policies
are to be based. Policy-makers, their partner public-health
experts and consumers alike seek rational guides to set
priorities for health care in a context of limited resources.
They need to evaluate the outcomes of a range of inter-
ventions and health-care reforms, monitoring changes
over time at local, national, regional or global levels.
Clearly, estimation of needs for health services and of the
costs and effectiveness of these services requires indica-
tors that go beyond measures of death rates or diagnosis
alone and takes into account the effects of disease and
health care upon people’s ability to function normally.
GBD 1990
Recognising and in response to these requirements, the
World Bank in collaboration with WHO and the Harvard
School of Public Health conducted the first global burden
of disease study in 1990 (GBD 1990) [12, 13]. It was
designed with three principal goals in mind: first, to pro-
vide information on non-fatal health outcomes for debates
on international health policy, which had until then
focused on mortality; second, to develop unbiased epi-
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demiological assessments for major disorders; and third,
to quantify the burden of disease with a measure that
could also be used for cost-effectiveness analysis.
Burden of disease has traditionally been measured, in
national and international health statistics, only in terms of
incidence/prevalence and mortality. These are indicators
well suited to acute diseases that either cause death or
resolve with full recovery; their use for chronic and dis-
abling diseases, however, is subject to serious limitations.
This is particularly true for mental and neurological disor-
ders, which more often cause lasting disability than prema-
ture death. GBD 1990 therefore employed a wider set of
indicators, both epidemiological and demographic: preva-
lence and incidence rates, life-expectancy estimates based
on probabilities of death in different age groups and dis-
ability-adjusted life expectancy. As well as generating the
most comprehensive and consistent set of estimates of mor-
tality and morbidity by age, sex and world region ever [13],
GBD 1990 introduced a new metric – disability-adjusted
life years (DALYs) – as a summary measure of population
health [10]. DALYs represent one way to account for the
chronicity of disorders and the disability they cause.
DALYs, YLLs and YLDs
DALYs combine information on impact of illness by
adding years lived with disability from incident cases of
the health condition (YLDs) to years of life lost due to
premature mortality (YLLs). One DALY is the equivalent
of one lost year of one person’s healthy life, whether this
loss is through early death by one year from a state of full
health or through living x years in a state of full health
reduced by 1/x. Thus:
1 YLL=1 year of life lost to early death
1 YLD=1 year lived with disability
(for example, 10 years lived with 10% disability or 
2 years lived with 50% disability)
DALYs (burden)=YLLs (mortality)+YLDs (disability)
DALYs are a health-gap measure. The population bur-
den of disease expressed in DALYs – the sum, in the pop-
ulation, of all YLLs and all YLDs [10, 13] – is a measure-
ment of the gap between current health status in that pop-
ulation and an ideal situation where everyone lives into old
age free from disease and disability. The appeal of DALYs
is as a tool in health policy: they translate epidemiological
data into information useful to decision-making. Based on
a universal measure of time – life years – DALYs provide
a common currency enabling priorities for health services
to be determined and, for purposes of health-care resource
allocation, the effectiveness of interventions assessed rela-
tive to one another across a wide range of health problems
[10–12]. However, DALYs are but an aid to decision-mak-
ing; they do not provide complete support for decisions
because they cannot incorporate all the values relevant to
those decisions. Murray and Lopez reviewed the applica-
tion of DALYs and other developments in the measure-
ment of burden of disease [13].
Estimating YLDs is the most difficult component of bur-
den of disease analysis using this methodology. The data
needed for calculating YLDs are disability incidence, dura-
tion and severity distribution, together with age at onset, all
of which must be disaggregated by age and gender. These in
turn require estimates of incidence, remission and case-
fatality rates by age and gender, all of which are not neces-
sarily constant between populations whilst, often, fragment-
ed and partial estimates are available from different studies.
Most important of all, meaningful calculation of YLDs
depends also on a clear definition of the disorder under con-
sideration in terms of case or episode, and severity accord-
ing to disease stage where these are related; it is then neces-
sary, but often difficult, to ensure that available incidence or
prevalence data relate to the same case definition.
A specific software tool, DisMod, has been developed
to assist internally consistent estimates of YLDs [10]. The
basic formula is
YLDs=IxDWxL
where I is the number of incident cases in the reference
period, DW is the disability weight applied to the disorder
(in the range 0–1, where 0 is no disability and 1 is total
and absolute disability) and L is the average duration of
disability associated with the disorder measured in years.
Disability weights
WHO embarked on large-scale efforts to improve the
methodological and empirical basis for the valuation of
health states, undertaking 61 surveys in 55 countries.
Empirical data for health-state valuations are scarce,
whilst a number of methodological problems have
emerged from various research efforts. In order to address
both of these challenges WHO, in collaboration with
Member States, initiated a data-collection strategy involv-
ing general population surveys combined with more
detailed surveys among respondents with high levels of
educational attainment in the same sites. In household sur-
veys, these individuals provided descriptions for a series
of hypothetical health states along seven core domains of
health, followed by valuations of these states using a sim-
ple visual analogue scale. The more detailed surveys
included more abstract and cognitively demanding valua-
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tion tasks that had limited reliability in general population
surveys but have been applied widely in industrialised
countries among convenience samples of educated
respondents [10, 14].
Data sources
Comprehensive and consistent estimates for incidence and
point prevalence are the key to accurate estimation of
YLDs. Murray et al. [10, 13] specified a range of data
sources that are or may be used.
Disease registers record new cases of disease based on
reports by physicians and/or laboratories. They exist
mostly as aids to the control of infectious diseases such as
tuberculosis, and for cancer and congenital anomalies, but
also record some relatively rare diseases such as cystic
fibrosis and thalassaemia. In some cases they accurately
record incidence and prevalence.
Population surveys, usually by interview, provide self-
reported information on diseases, disabilities and impair-
ments. There are commonly large differences between con-
cepts of a disease held by members of the general public
and the defined disease entity for which information is
intended to be collected. Self-reported data, which may be
based on self-diagnosis, are therefore not readily compara-
ble between countries or cultures and often present difficul-
ties in attributing impairment to its underlying cause. In
general they fall short of quality requirements for YLD cal-
culations, but may provide the only (and therefore the
“best”) information available.
Population-based epidemiological studies are the most
useful information sources. Particularly, longitudinal stud-
ies of the natural history of a disease can provide a wealth
of information on incidence, average duration, severity
distribution, remission and case fatality – essentially all
that YLD calculations require. Such studies are relatively
rare because they are very costly to do well. Many that do
exist were conducted in a selected region or town to facil-
itate sample access, and therefore case ascertainment,
whilst limiting cost; judgement is then needed in extrapo-
lating results to a wider population.
Health facility data, derived from consultations, may
be relatively precise but are not very helpful in estimating
burden. Facility-based data – unless health-system cover-
age is near complete, which is rare – will always be drawn
from biased samples and are highly likely to misrepresent
the disability present in the wider community. Hospital
deaths are unlikely to be useful for the same reason. There
are exceptions: the quality of hospital data may be good
for conditions inevitably treated in hospital: for example,
perinatal complications, meningitis, stroke, myocardial
infarction, surgical conditions and serious injuries.
GBD 2000
WHO made a second assessment of the global burden of
disease in 2000 (GBD 2000). The three goals of GBD 1990
[10, 12, 13] remained central, if differently expressed:
- to decouple epidemiological assessment of the magni-
tude of health problems from advocacy by interest
groups of particular health policies or interventions;
- to include in international health-policy debates infor-
mation on non-fatal health outcomes along with infor-
mation on mortality;
- to undertake the quantification of health problems in time-
based units that can also be used in economic appraisal.
However, GBD 2000 had specific additional, albeit
related, objectives:
- to develop internally consistent estimates of mortality
from 135 major causes of death, disaggregated by age and
gender, for the world and for major geographic regions;
- to develop internally consistent estimates of incidence,
prevalence, duration and case fatality for over 500
sequelae resulting from these causes;
- to describe and value the health states associated with
these sequelae of diseases and injuries;
- to quantify the burden of premature mortality and dis-
ability by age, gender and region for the 135 major
causes or groups of causes;
- to analyse the contribution to this burden of major
physiological, behavioural and social risk factors by
age, gender and region; 
- to develop alternative projection scenarios of mortali-
ty and non-fatal health outcomes over the next 30
years, disaggregated by cause, age, gender and region.
YLD estimates for GBD 2000 were based largely on the
GBD 1990 disability weights, although the disability
weight for migraine was developed for GBD 2000 for the
first time. One of us Dr Leonardi was responsible for data
collection for estimation of the burden of migraine and for
the development of the disability weight for migraine under
the coordination of Drs B. Ustün, C. Mathers and C.J.L.
Murray of who and in collaboration with leading headache
experts worldwide. After several discussions it was decided
that a 3x3 table of frequency and severity (low, moderate
and high in each case) would help to develop the weight for
migraine. Comparison with criteria adopted for other fluc-
tuating diseases such as asthma balanced the weighting of
migraine against those of other disorders
Migraine: the epidemiological evidence
To measure the burden of migraine for GBD 2000, specific
methods were developed. A protocol was set out for a com-
plete and systematic review of all available published and
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non-published papers of valid population studies on
headache disorders. The search for data sources included
the databases Medline, Pre-medline, Embase and Cinhal.
The strategy was to seek all published articles from all
regions of the world in English, (although some grey liter-
ature in other languages has been reviewed), using the
expanded MESH terms: headache, migraine, tension-type
headache, chronic daily headache, (mortality/epidemiolo-
gy), plus Africa, China, India, Europe, Eastern Europe,
Japan, America, plus focus studies, epidemiological stud-
ies, burden of disease; and key words: migraine, tension-
type headache, epidemiology, mortality, disability, burden
of disease. Unpublished papers were found through expert
advice from IHS members and from WHO materials and
guidance was obtained from the Italian National
Neurological Institute “Carlo Besta” and the WHO library
to verify that no obtainable data were missing.
Articles were selected or rejected according to pre-set
inclusion criteria so that the inquiry was not data-driven:
- population-based studies (sample size n>1000) that
used IHS diagnostic criteria or a modified set of crite-
ria based on IHS recommendations [15];
- studies that reported prevalence (whenever possible,
where there was specification of the period covered: 1
month, 12 months, lifetime, data were converted into
point prevalences);
- studies with explicit methodology using samples that
were either random or demonstrated to be nationally or
regionally representative;
- data presented on any or all of incidence, prevalence,
remission rate, case fatality rate, natural history, age,
gender, region or country.
We present here a summary of the epidemiological
evidence of migraine. Whilst this helps to create aware-
ness of the size of the global public-health problem that
migraine represents, it also highlights the need for further
epidemiological studies in many parts of the world.
Case definition
The definition of migraine established in the WHO’s
International Classification of Disease and related health
conditions, 10th edn, 1992 (ICD-10) as well as the diag-
nostic criteria from the IHS classification of 1988 [15]
were used so that epidemiological data were taken from
surveys employing similar and compatible definitions.
Migraine incidence
There were few studies of migraine incidence. Although
cross-sectional data can be used to derive incidence esti-
mates, they are better obtained from longitudinal studies [16,
17]. Stewart et al. estimated migraine incidence using report-
ed age-at-onset data from a prevalence study, admitting the
inherent limitations of imperfect recall, failure to report true
symptoms and the reporting of symptoms not actually expe-
rienced [18]. In males, the incidence of migraine with aura
peaked at around 5 years of age at 6.6/1000 person/years;
incidence of migraine without aura peaked at 10/1000 per-
son/years between 10 and 11 years. New cases of migraine
were uncommon in men in their 20s. In females, the inci-
dence of migraine with aura peaked higher (14.1/1000 per-
son/years) but later (between 12 and 13 years) and of
migraine without aura also (18.9/1000 person/years between
14 and 17 years). On this evidence, migraine begins earlier
in males than in females and migraine with aura begins ear-
lier than does migraine without aura.
Stang et al. [19, 20] used the linked medical records
system in Olmstead County, Minnesota, to identify those
who sought medical care for migraine. Incidences were
lower: 1.5–2/1000 person/years for men under 30 years of
age and 3–6/1000 person/years in women under 30. This
would be expected: many people with migraine do not
consult doctors or receive a medical diagnosis [17]. Peaks
were later than found by Stewart [21], showing that med-
ical diagnosis may occur long after onset.
Migraine prevalence
In the decade prior to GBD 2000, several epidemiological
studies published estimates of migraine prevalence that
varied widely [16, 17, 22–28]. In 1995, a meta-analysis of
24 studies included only five that used IHS diagnostic cri-
teria [29], and revealed that case definition, along with
differing age and gender distributions of the study sam-
ples, explained 70% of the variation in migraine preva-
lence between studies. Migraine prevalence studies pose a
number of methodological challenges and the main obsta-
cle has been case definition. Fortunately this has been par-
tially overcome by the IHS classification [15] and, in our
methodology, because case definition so powerfully influ-
ences prevalence estimates, we focused on studies that
used IHS diagnostic criteria.
In a second meta-analysis confined to studies using
IHS criteria, in gender-specific models (females and
males were modelled separately), age and geography
accounted for much of the variation in prevalence [30].
Influence of race and geography
Prevalence rates of IHS-defined migraine are relatively con-
sistent in Western countries, varying from 4% to 9.5% in
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men and from 11.2% to 25% in women [17–19, 21–23, 27,
31]. In the greater Copenhagen study, lifetime prevalences
were 8% for men and 25% for women [30]. One-year peri-
od prevalences were 6% and 16% respectively. In the USA,
the first American Migraine Study, based on data collected
in 1989, used questionnaires mailed to 15 000 households
selected to be representative of the US population [18].
Migraine diagnoses were based on modified IHS criteria.
Prevalences were 6% in men and 17% for women, closely
matching the estimates of Rasmussen [30]. A follow-up
study, the American Migraine Study II, used virtually iden-
tical methodology 10 years later with very similar findings
[27]. In France, Henry et al. reported prevalences of IHS-
defined migraine as 4% in men and 11.9% in women [24].
In this study, diagnoses were assigned by lay interviewers
using a validated algorithm: for the diagnostic variant of
“borderline migraine”, prevalence estimates were higher –
6.1% in men and 17.6% in women – again remarkably close
to the findings of Rasmussen [30] and Stewart et al. [29].
Migraine prevalence varies by race and geography but
there is some question as to how much. In the USA it was
found to be highest in Caucasians, intermediate in African
Americans and lowest in Asian Americans [18]. The sec-
ond meta-analysis referred to above suggested migraine
was most common in North and South America, similar in
Europe, lower in Africa and often lowest in studies from
Asia (Fig. 1) [17, 27]. The magnitude of the disease in
Latin America has been difficult to assess because good
studies are scarce. The problem is compounded in areas
where large segments of the population do not have access
to doctors and facilities for diagnosis are not available.
Nevertheless, recent studies from Brazil, Chile and
Ecuador show that headache is highly prevalent in these
countries and imposes a large economic burden on health-
care systems stretched to their limits. As in developed
countries, migraine and chronic tension-type headache are
the most common subtypes of headache disorders in South
America [32–36]. Tekle Haimanot reported that “literature
on prevalence and health burden in Africa is scanty” [37].
Because of the lower life expectancy in African countries,
disease prevalence is studied in relatively young popula-
tions. Epidemiological surveys in Nigeria, Ethiopia,
Tanzania and Zimbabwe produced prevalences of
3%–6.9% among adults, with all studies reporting a female
preponderance (male to female ratios of 1:1.3 to 1:2.8).
Tekle Haimanot considered migraine with aura to be rela-
tively rare in Africans [37]. In Asia, whilst studies in Hong
Kong, Malaysia and Japan recorded lower prevalences
[38–40], more recent studies [41] in Turkey [42, 43],
Oman [44], Saudi Arabia [45] and Iran [46] have found
higher prevalences than those included in the meta-analy-
sis, more in line with Western estimates. The influence of
reporting bias on these findings cannot be excluded.
Influence of age and gender
Before puberty, migraine prevalence is higher in boys than
in girls; as adolescence approaches, incidence and preva-
lence increase more rapidly in girls than in boys [47–49].
Prevalence continues to increase through early adult life
until approximately 40 years of age, after which it
declines [18, 31]. The gap between peak incidence in
childhood to adolescence and peak prevalence in middle
life indicates that migraine is a condition of long duration.
The female to male migraine prevalence ratio there-
fore varies with age [18, 21, 31]. The onset of hormonal
changes associated with menses probably accounts for
much of this variation [50] although hormonal factors
cannot be the sole cause: differences persist to age 70
years and beyond, well after cyclical hormonal changes
can be a factor [21, 51].
Regions of the world as subdivided in the Burden of
Disease study
As reported in Ustun and colleagues in 2004 [52], for geo-
graphic disaggregating of the GBD 2000 the six regions of
the world (Africa, Americas, Eastern Mediterranean,
Europe, South East Asia, Western Pacific) were subdivided
into 17 epidemiological subregions based on levels of mor-
tality (children under 5 years and adults 15–59 years). Five
mortality strata were defined in terms of quintiles of the
distribution of child and adult mortality. When these mor-
tality strata are applied to the 6 WHO regions, they produce













































ease epidemiological analysis, 2 of these regions were fur-
ther subdivided: EurB (WHO European region) into EurB1
and EurB2, the latter including the central Asian states.
WPRB (WHO Western Pacific Region) into WPRB1
(mainly China), WPRB2 (South East Asian Countries) and
WPRB3 (Pacific Islands). A detailed table of these epi-
demiological subregions can be downloaded from the
WHO website at http://www.who.int/whr/2003/en/mem-
ber_states_182-184_en.pdf.
The World Health Report 2001 and the burden of
migraine
In 2001 WHO published the annual World Health Report
entitled Mental health: new understanding, new hope
[11]. It took the findings of GBD 2000 and discussed the
burden attributable to the 135 health conditions included
therein, but focused on mental and neurological disorders.
The report revealed how the burdens these disorders
imposed on population health were highlighted by esti-
mates that moved from a mortality to a disability perspec-
tive using the GBD study methodology. This acknowl-
edgement of disability as an equally important part of the
burden of disease, and its inclusion in burden measure-
ment, substantially increased the relative importance of
non-communicable diseases, which generally cause much
more disability than mortality and were invisible in past
estimates of burden based on mortality measures alone.
The report accordingly demonstrated that a number of
mental and neurological disorders are amongst the most
disabling. In the GBD 1990 estimates, these disorders
accounted for 10.5% of the total DALYs worldwide
resulting from all diseases and injuries – a figure that for
the first time indicated the high burden imposed by men-
tal and neurological disorders. The re-estimate of GBD
2000 was 12.3% and from an analysis of trends it is evi-
dent that this burden will increase rapidly in the future,
with projections indicating 15% by the year 2020 [13].
Whilst these disorders collectively account in the
Report for 30.8% of all YLDs worldwide, six of them fea-
tured in the top 20 causes of disability: unipolar depres-
sive disorders, alcohol-use disorders, schizophrenia,
bipolar affective disorder, Alzheimer’s and other demen-
tias, and migraine [11]. Migraine defined by IHS criteria
[15], included for the first time and contributing 1.4% of
all YLDs, is the 19th cause of disability in both sexes of
all ages and 12th, accounting for 2.0% of YLDs, in
women (Table 1).
With the publication of the World Health Report
2001, and this evidence of the high burden of migraine,
WHO recognised headache disorders as a high-priority
public-health problem. They deserve this recognition:
currently they are low in order in the queue for health-
care resource allocation.
Our earlier comments made clear that, whilst DALYs
translate epidemiological data into usable information for
health policy, their validity depends crucially upon the qual-
ity of those data. Where epidemiological studies are lacking
Table 1 Leading causes of years lived with disability (YLDs)
Both sexes, all ages % of total Females, all ages % of total
1. Unipolar depressive disorders 11.9 1. Unipolar depressive disorders 14.0
2. Hearing loss, adult onset 4.6 2. Iron-deficiency anaemia 4.9
3. Iron-deficiency anaemia 4.5 3. Hearing loss, adult onset 4.2
4. Chronic obstructive pulmonary disease 3.3 4. Osteoarthritis 3.5
5. Alcohol use disorders 3.1 5. Chronic obstructive pulmonary disease 2.9
6. Osteoarthritis 3.0 6. Schizophrenia 2.7
7. Schizophrenia 2.8 7. Bipolar affective disorder 2.4
8. Falls 2.8 8. Falls 2.3
9. Bipolar affective disorder 2.5 9. Alzheimer’s and other dementias 2.2
10. Asthma 2.1 10. Obstructed labour 2.1
11. Congenital abnormalities 2.1 11. Cataracts 2.0
12. Perinatal conditions 2.0 12. Migraine 2.0
13. Alzheimer’s and other dementias 2.0 13. Congenital abnormalities 1.9
14. Cataracts 1.9 14. Asthma 1.8
15. Road traffic accidents 1.8 15. Perinatal conditions 1.8
16. Protein-energy malnutrition 1.7 16. Chlamydia 1.8
17. Cerebrovascular disease 1.7 17. Cerebrovascular disease 1.8
18. HIV/AIDS 1.5 18. Protein-energy malnutrition 1.6
19. Migraine 1.4 19. Abortion 1.6
20. Diabetes mellitus 1.4 20. Panic disorder 1.6
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or of questionable accuracy, degrees of uncertainty affect the
calculation of DALYs and YLDs. GBD 2000 estimates for
mental and neurological disorders, like those of GBD 1990,
were subject to the variable quality of the available preva-
lence data summarised above: large gaps prevailed in many
regions of the world; uncertainties also existed about the
severity distributions of these disorders. These uncertainties
reflected, in particular, the limitations of self-report instru-
ments and their questionable ability to classify symptoms in
a comparable way across and between populations, and pos-
sibly erroneous extrapolation of survey results from popula-
tion subsets to broader population groups. Lack of informa-
tion to assess the severity of disability attributable to the dis-
orders of interest was also a factor.
Where inadeguate for a region were available, experts
on headache, and on the other neuropsychiatric condi-
tions, were encouraged to make informed estimates.
Frequently, age-related patterns of incidence and preva-
lence were assumed to be similar from one region to
another despite differences in overall incidence or preva-
lence. In the worst cases, where no information whatsoev-
er was available from a region, estimates were made by
extrapolation from other regions.
Despite these uncertainties, it has been clearly shown
that the disability caused by mental and neurological disor-
ders is high in all regions of the world. As a proportion of
the total, it is lower in developing countries, mainly because
of the large burden of communicable, maternal, perinatal
and nutritional conditions in those regions. Even so, mental
and neurological disorders cause 17.6% of all YLDs in
Africa. These disorders are not the preserve of any special
group: they are truly universal, found in people of all
regions, all countries and all societies, in women and men at
all stages of life, among rich and poor and among people liv-
ing in urban and in rural areas. The notion that these disor-
ders are problems of industrialised and wealthier parts of the
world is simply wrong. The belief that rural communities,
relatively unaffected by the fast pace of modern life, are less
affected by these disorders is also incorrect [11].
The socioeconomic impact of many of these disorders,
with migraine high amongst them, is wide-ranging, long-
lasting and enormous. They impose a range of costs on
individuals, families and communities as a whole. Part of
this economic burden is obvious and measurable, whilst
part is almost impossible to quantify. Among the measur-
able components are health- and social-service needs, lost
employment and reduced productivity, impact on families
and demands upon caregivers, and the negative impact of
premature mortality [3].
Indirect costs, especially those arising from productiv-
ity loss, account for a larger proportion of overall costs
than direct costs. WHO defines burden of disease to
include the economic and emotional difficulties that a
family experiences as a result of them, as well as the lost
opportunities – the adjustments and compromises that pre-
vent other family members from achieving their full
potential in work, social relationships and leisure [11].
Ideally, all of these would be captured in burden estimates
by allowing for them in disability weightings. In reality,
all economic evaluations are most certainly underesti-
mates, as lost opportunity costs to individuals and families
are not taken into account whilst being vital to a full
understanding of the implications of a disorder.
Disability in headache disorders and the International
Classification of Functioning, Disability and Health (ICF)
Knowledge of prevalence, incidence, natural history and
prognosis of many diseases remains limited because of the
lack of studies and the methodological weaknesses of
many that are done. Epidemiological data on headache dis-
orders, as already highlighted in this paper and as for
almost all mental and neurological disorders, are scarce in
many parts of the world and based on inconsistent sam-
pling frames and definitions of prevalence rates (e.g., life-
time or point prevalence). We recited the principal method-
ological deficiencies earlier. New epidemiological studies
are required; but, especially if these are to demonstrate
burden and not merely prevalence of disease, methodolog-
ical improvements are called for.
After many years of use of ICIDH 1980, the Inter-
national Classification of Impairments, Disabilities and
Handicaps that had been developed by WHO for field trials
only and after its extensive revision, involving researchers
in more than 65 countries, WHO published the International
Classification of Functioning, Disability and Health (ICF),
approved by the World Health Assembly in May 2001.
ICF is a classification standard and framework for
measuring health and disability [53]. It acknowledges the
shift in international concern about health-care outcomes
toward the consideration of functioning and disability at
the level of the whole human being in day-to-day life. It
meets the need for universally applicable classification
and can be related to many specific assessment tools, both
for activity levels and for overall levels of participation by
the individual in the basic areas and roles of social life. It
is an important development, particularly for those
endeavouring to apply appropriate measures to health
conditions with low mortality but high disability.
Applying ICF to migraine and other headache disorders
Studies have shown that diagnosis alone does not predict
health-service needs, lengths of hospitalisation, levels of
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care requirement or outcomes. We also know that diagno-
sis is not an accurate predictor of receipt of disability ben-
efits, work performance, potential for return to work or
the likelihood of social integration. So, a purely medical
classification of diagnoses does not provide the informa-
tion required for planning and management purposes,
especially in chronic and disabling diseases. The
International Headache Society (IHS) has a long experi-
ence in disease classification [15], and in collaborating
with WHO to bring headache disorders into the neurolog-
ical adaptation of ICD-10 (ICD-10 NA). This classifica-
tion has been very useful in many ways, but it classifies
diseases strictly by diagnosis. It does not, and is not
intended to, consider the functioning and disability
aspects of the many headache disorders it includes.
However, when data on functioning are taken into
account along with diagnosis, the predictive power and
understanding of needs and outcomes are increased. It is
beyond doubt that management and provision of services
for migraine would benefit from an informative measure-
ment of its functional consequences. ICF, as an interna-
tionally recognised tool and a common language to define
health and health-related domains, could be the instru-
ment to help researchers in the headache field. Classifying
functioning and disability in relation to headache disor-
ders could:
- provide a common framework for research, clinical
work and social policy;
- better define the need for health and social services
and related interventions;
- characterise physical, mental, social, economic and
environmental interventions that would improve levels
of human functioning and therefore lives;
- ensure cost-effective provision and management of
health-care and related services;
- better define health outcomes in terms of bodily, per-
sonal and social functioning;
- identify environmental barriers or facilitators for
headache sufferers.
Disability is a multi-dimensional construct. It encom-
passes a range of aspects at body, individual and society
levels, from self-care to work capacity, from moving
around at home to being able to travel or participate in
sport, and from pursuing household activities to voting. It
is not easy to measure all the dimensions of disability
resulting from a disease like migraine but ICF provides
the basic framework. Included is the key role of environ-
ment: according to ICF’s construct (Fig. 2), any health
condition in an unfavourable environment can cause dis-
ability. An adverse environment for migraine sufferers
(apart from immediately deleterious conditions such as
excessive noise and bright light) could be, for example,
and often is, lack of necessary health-care facilities, of
accurate diagnosis, of care or required drugs, but it could
also be, and again often is, not being taken seriously.
Social planners and service agencies increasingly recog-
nise that reducing disability in a population involves not
only providing necessary therapies, but also modifying
social and physical environments as a means to enhancing
people’s levels of functioning. Use of ICF to highlight
these additional and so-far unquantified negative aspects
of being a migraine sufferer would lead to more complete
estimates of burden and is probably a prerequisite for due
allocation of health-care resources.
As shown in Fig. 2, working on Environmental Factors
is one of the key points in the biopsychosocial model of
health and disability. ICF is a classification but at the same
time is a common language to define health and health-
related domains: because of its features, it can be consid-
ered as a tool for putting concepts in order. ICF doesn’t
allow users to rate the severity of a disease, but gives the
possibility to define which are the elements in the persons’
lives that are more problematic, defining them as impair-
ments, activity limitations and participation restrictions.
The concepts of impairments is commonly shared with
ICD, but with a different meaning: in ICF, an impairment
is viewed only with descriptive aims and defined them as
problems with function or structure; in ICD impairments
are defined, with diagnostic aims, in terms of sign, symp-
toms and abnormal clinical or laboratory findings. In using
ICF, what users have to do is to translate data deduced
from specific assessments into ICF codes, and to link their
results in assigning qualifiers [54]. This is very important
because ICF is not an assessment tool, but has to be based
on specific assessment tools.
In the context of to activity and participation [55],
limitation and restrictions are defined as problems and
difficulties that an individual could meet in doing activi-
ties or being involved in life situations. These domains
are mostly out of the medical perspective, but at the same
time represent essential conditions in which a disease has
its psychosocial effects: difficulties at work, problem
with interpersonal relationships, limitations in doing














household activities, problems in carrying out a full and
productive life, for example, represent an important rea-
son to need a treatment for migraine. ICF is the only
international tool that encompasses these domains, whose
consideration is a central element in curing and caring for
a person with migraine.
Finally, Environmental Factors [56]. They are quali-
fied as facilitators or barriers, and their consideration
gives ICF’s user the possibility to define a plan of care,
centred on the real needs of the persons, and not on pre-
defined paths, which are prepared mostly in consideration
of available services in health systems and very often do
not consider migraine as a chronic disease needing health
and social services.
Place the person in the centre: this is the most impor-
tant concept that we want to convey with ICF. Because a
rehabilitation or care service could meet the needs of the
majority of persons with migraine, but it is frequent that
interventions set for one may not fit for others, for all.
One of the central possible application of ICF in the
field of migraine care could be, from our point of view,
that of health-related data management [57–60]. ICF is a
tool that could be very helpful, as we have shown, in plan-
ning intervention centred on the persons, but is a very
complete tool to manage great amounts of information
too. WHO experts suggest to insert ICF structural forms in
administrative databases, because this is the way to define
the impact of environmental factors in large populations:
this will be very useful in deciding how to assign meagre
economic resources, so as to compare different types of
treatment, and the same type of treatment in different set-
tings or countries. Using Functioning as an indicator is the
way to capture information on persons’ health that is com-
prehensive of social and psychological aspects: ICF clas-
sification gives the theoretical and practical basis to col-
lect this information in a coherent and standard way. This
will help in reaching the objective of the WHO-IHS-EHF-
WHA Lifting the Burden Campaign that says that it is nec-
essary to improve access to health-care services offering
correct diagnosis and effective management whilst
enhancing social understanding of headache disorders.
This can be done also recognising that gaps exist every-
where between needs of people with headache and provi-
sion of health care for headache.
Conclusions
Headache disorders are common, in many cases lifelong
conditions and associated with recognisable burdens that
include personal suffering, disability and impaired quality
of life. With the publication of data on burden of migraine
in WHR 2001, WHO recognises headache disorders as a
high-priority public health problem and as such they
deserve higher attention, but low priority is given to them
in the queue for health care. It is right to consider the
impact of headache disorders on public health from the
humanistic perspective of suffering rather than limit the
discussion to one focused on cost.
Using WHO’s criteria and methods for measuring bur-
den of disease in DALYs, headache disorders can be
placed correctly in the context of other mental and neuro-
logical disorders and other chronic illnesses. In order to
know the full burden attributable to headache disorders,
however, further epidemiological work must be conducted
around the world and this must encompass assessments of
clinical, economic and humanistic impacts. The
International Classification of Functioning, Disability and
Health (ICF) provides a means of doing this.
ICF can usefully contribute to the debate on service
provision and policy development for headache, to devel-
opment of intervention strategies, to economic analyses
and to scientific research on functioning and disability in
headache disorders.
It is hoped that further collaboration between the sci-
entific and lay non-governmental organisations such as
the International Headache Society and World Headache
Alliance will lead to implementation of ICF in their joint
objective to reduce the burden of headache worldwide.
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